Novartis Signs mRNA Deal With China's Abogen

In October 2026, Novartis signed a licensing deal with the Chinese company Abogen for mRNA therapies, worth up to $7.8 billion. The agreement covers rights to mRNA-based treatments developed by Abogen. The deal is one of the largest recent partnerships between a global pharmaceutical company and a Chinese biotech firm.